Foveal Cone Structure in Patients With Blue Cone Monochromacy.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
03 Oct 2022
03 Oct 2022
Historique:
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
1
11
2022
Statut:
ppublish
Résumé
Blue cone monochromacy (BCM) is a rare inherited cone disorder in which both long- (L-) and middle- (M-) wavelength sensitive cone classes are either impaired or nonfunctional. Assessing genotype-phenotype relationships in BCM can improve our understanding of retinal development in the absence of functional L- and M-cones. Here we examined foveal cone structure in patients with genetically-confirmed BCM, using adaptive optics scanning light ophthalmoscopy (AOSLO). Twenty-three male patients (aged 6-75 years) with genetically-confirmed BCM were recruited for high-resolution imaging. Eight patients had a deletion of the locus control region (LCR), and 15 had a missense mutation-Cys203Arg-affecting the first two genes in the opsin gene array. Foveal cone structure was assessed using confocal and non-confocal split-detection AOSLO across a 300 × 300 µm area, centered on the location of peak cell density. Only one of eight patients with LCR deletions and 10 of 15 patients with Cys203Arg mutations had analyzable images. Mean total cone density for Cys203Arg patients was 16,664 ± 11,513 cones/mm2 (n = 10), which is, on average, around 40% of normal. Waveguiding cone density was 2073 ± 963 cones/mm2 (n = 9), which was consistent with published histological estimates of S-cone density in the normal eye. The one patient with an LCR deletion had a total cone density of 10,246 cones/mm2 and waveguiding density of 1535 cones/mm2. Our results show that BCM patients with LCR deletions and Cys203Arg mutations have a population of non-waveguiding photoreceptors, although the spectral identity and level of function remain unknown.
Identifiants
pubmed: 36301530
pii: 2783794
doi: 10.1167/iovs.63.11.23
pmc: PMC9624264
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Subventions
Organisme : Medical Research Council
ID : MR/R012121/1
Pays : United Kingdom
Organisme : NEI NIH HHS
ID : P30 EY001730
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR016511
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001436
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM080202
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY017607
Pays : United States
Organisme : NEI NIH HHS
ID : T32 EY014537
Pays : United States
Organisme : Wellcome Trust
ID : 099173/Z/12/Z
Pays : United Kingdom
Références
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7951-7956
pubmed: 30944223
Hum Gene Ther. 2013 Dec;24(12):993-1006
pubmed: 24067079
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Am J Ophthalmol Case Rep. 2017 Sep;7:14-19
pubmed: 29057371
Retina. 2017 Mar;37(3):436-443
pubmed: 27780174
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4238-4248
pubmed: 30128495
J Vis. 2020 Jul 1;20(7):34
pubmed: 32735342
Acta Ophthalmol (Copenh). 1988 Aug;66(4):450-6
pubmed: 3264103
Sci Adv. 2020 Sep 9;6(37):
pubmed: 32917686
Curr Biol. 2021 Sep 27;31(18):4188-4193.e3
pubmed: 34343479
J Physiol. 1965 Dec;181(3):576-93
pubmed: 5880378
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):
pubmed: 35197287
J Comp Neurol. 2000 Oct 2;425(4):545-59
pubmed: 10975879
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):383-396
pubmed: 30682209
Vis Neurosci. 2004 May-Jun;21(3):205-16
pubmed: 15518190
Opt Express. 2020 Dec 21;28(26):39326-39339
pubmed: 33379485
Biomed Opt Express. 2018 Jul 18;9(8):3740-3756
pubmed: 30338152
J Comp Neurol. 1991 Oct 22;312(4):610-24
pubmed: 1722224
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):2992-3001
pubmed: 27273598
Science. 1989 Aug 25;245(4920):831-8
pubmed: 2788922
Vision Res. 2017 Mar;132:53-61
pubmed: 27286921
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4580-92
pubmed: 14507907
Invest Ophthalmol Vis Sci. 1997 May;38(6):1074-81
pubmed: 9152227
Nat Neurosci. 2010 Feb;13(2):156-7
pubmed: 20023654
J Opt Soc Am A. 1987 Aug;4(8):1503-13
pubmed: 3625330
Hum Genet. 1985;69(3):255-62
pubmed: 3872255
Invest Ophthalmol Vis Sci. 2014 May 20;55(7):4186-98
pubmed: 24845642
Vision Res. 2011 Apr 13;51(7):633-51
pubmed: 21167193
Acta Ophthalmol. 2016 Dec;94(8):748-754
pubmed: 27350263
Prog Retin Eye Res. 2012 Nov;31(6):622-60
pubmed: 22772022
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20948-53
pubmed: 19934058
Hum Mutat. 2014 Nov;35(11):1354-62
pubmed: 25168334
J Comp Neurol. 1990 Feb 22;292(4):497-523
pubmed: 2324310
Clin Genet. 1990 Oct;38(4):281-6
pubmed: 1980096
J Comp Neurol. 1999 Jan 25;403(4):502-16
pubmed: 9888315
Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):29
pubmed: 35072690
J Vis. 2017 Jan 1;17(1):30
pubmed: 28129414
Biomed Opt Express. 2022 Aug 01;13(8):4445-4454
pubmed: 36032569
Invest Ophthalmol Vis Sci. 2014 Oct 02;55(11):7303-11
pubmed: 25277229
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):713-9
pubmed: 18235019
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3984-95
pubmed: 27479814
Science. 2018 Oct 12;362(6411):
pubmed: 30309916
Invest Ophthalmol Vis Sci. 2012 Dec 05;53(13):8006-15
pubmed: 23139274
Prog Retin Eye Res. 2021 Jul;83:100920
pubmed: 33161127
Invest Ophthalmol Vis Sci. 2014 Jun 06;55(7):4244-51
pubmed: 24906859
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3853-63
pubmed: 27447086
J Comp Neurol. 2019 Jan 1;527(1):38-51
pubmed: 28074469
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2631-2640
pubmed: 31237654
Nat Neurosci. 2002 Apr;5(4):364-70
pubmed: 11914722
Invest Ophthalmol Vis Sci. 2021 Feb 1;62(2):8
pubmed: 33544131